AC Immune (ACIU) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings or view top-rated stocks.

1 brokerages have issued 12 month target prices for AC Immune's shares. Their ACIU share price forecasts range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next year. This suggests a possible upside of 451.7% from the stock's current price.
View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts.

AC Immune's stock was trading at $2.04 at the beginning of 2023. Since then, ACIU stock has increased by 42.2% and is now trading at $2.90.
View the best growth stocks for 2023 here.

AC Immune saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 455,000 shares, an increase of 17.3% from the August 31st total of 388,000 shares. Based on an average trading volume of 971,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.1% of the shares of the stock are short sold.
View AC Immune's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our ACIU earnings forecast.

AC Immune SA (NASDAQ:ACIU) released its quarterly earnings data on Friday, August, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.22).

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV).

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACIU stock can currently be purchased for approximately $2.90.

AC Immune (NASDAQ:ACIU) has a market capitalization of $242.50 million and generates $4.12 million in revenue each year. The company earns $-74,140,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

The company employs 126 workers across the globe.

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 345-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120.